Tenax Therapeutics, INC. (TENX) — 10-Q Filings

10-Q Filings (6)

• Tenax Therapeutics' Losses Mount Amid R&D Surge, Cash Position Strong — Nov 12, 2025 Risk: high
  TENAX THERAPEUTICS, INC. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $37.059 million, a substantial rise
• Tenax Therapeutics' Burn Rate Soars Amid R&D Push, Cash Reserves Up — Aug 13, 2025 Risk: high
  TENAX THERAPEUTICS, INC. reported a significant increase in net loss for the six months ended June 30, 2025, reaching $21.255 million, up from $7.374 million in
• Tenax Therapeutics Files Q1 2025 10-Q — May 14, 2025 Risk: medium
  Tenax Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business op
• Tenax Therapeutics Q3 2024 Update — Nov 13, 2024 Risk: high
  Tenax Therapeutics, Inc. filed a 10-Q for the period ending September 30, 2024. The company reported total assets of $4.8 million and total liabilities of $5.2
• Tenax Therapeutics Reports Q2 Loss, Announces Private Placement — Aug 13, 2024 Risk: medium
  Tenax Therapeutics, Inc. filed its Q2 2024 10-Q report on August 13, 2024. The company reported total assets of $5.18 million and total liabilities of $0.21 mil
• Tenax Therapeutics Q1 2024: Assets and Liabilities — May 14, 2024 Risk: medium
  Tenax Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2024. The company reported total assets of $4.8 million and total liabilities of $0.9 mill

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX